Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240512 · ClinicalTrials.gov registry record · NA
DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 534
- Enrollment target
NCT01240512: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01240512 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 534 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01240512, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 534 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, multicenter, 6-month follow-up trial of low (400 IU/day) versus high (4000 IU/day) dose vitamin D supplementation in individuals with pre- and early stage 1 hypertension and vitamin D deficiency. A total of 530 participants (265 participants per treatment arm) will be randomized between 3 sites. Approximately 2,250 participants will be screened between the 3 sites. Vital signs, 24-hour ambulatory blood pressure monitoring, clinical laboratory safety tests and adverse event assessments will be performed to evaluate the effectiveness of the two doses of vitamin D on blood pressure. Blood samples will be stored for future biomarker assessments. The total duration of the study is anticipated to be 18 months, assuming a 12 month enrollment period.
Interventions
- DRUG Cholecalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240512
The ClinicalTrials.gov registry entry for NCT01240512 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 534 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cholecalciferol is the first listed.
NCT01240512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240512 about?
NCT01240512 is a clinical study titled "DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension". This is a randomized, double-blind, multicenter, 6-month follow-up trial of low (400 IU/day) versus high (4000 IU/day) dose vitamin D supplementation in individuals with pre- and early stage 1 hypertension and vitamin D deficiency. A total of 530 participants (265 participants per treatment arm) wil...
What is the current status of trial NCT01240512?
This trial is currently completed. It is a NA study. The enrollment target is 534 participants. The study started on 2010-12. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01240512?
The interventions under investigation include: Cholecalciferol (DRUG).
Who is sponsoring clinical trial NCT01240512?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.